**Supplemental information** 

Extended BNT162b2 booster dosing generates a broader neutralizing antibody

response against SARS-CoV-2 variants of concern

Carl Graham<sup>1\*</sup>, Thomas Lechmere<sup>1\*</sup>, Aisha Rehman<sup>1</sup>, Jeffrey Seow<sup>1</sup>, Ashwini Kurshan<sup>1</sup>,

Isabella Huettner<sup>1</sup>, Thomas J.A. Maguire<sup>1</sup>, Jerry Tam<sup>1</sup>, Daniel Cox<sup>1</sup>, Christopher Ward<sup>1</sup>,

Mariusz Racz<sup>2</sup>, Anele Waters<sup>2</sup>, Christine Mant<sup>3</sup>, Michael H. Malim<sup>1</sup>, Julie Fox<sup>1</sup>, Katie J.

Doores<sup>1</sup>#

<sup>1</sup> Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's

College London, London, UK.

<sup>2</sup> Harrison Wing, Guys and St Thomas' NHS Trust, London, UK.

<sup>3</sup> Infectious Diseases Biobank, Department of Infectious Diseases, School of Immunology

and Microbial Sciences, King's College London, London, UK.

\* These authors contributed equally

# Corresponding author: katie.doores@kcl.ac.uk

Supplementary Figure S1: SARS-CoV-2 Spike-reactive memory B cells measured

**before and after vaccination. A)** Example FACS gating for pre-vaccination sample (visit 1)

and from post-vaccination sample (visit 3) from SARS-CoV-2 naïve individual. **B)** Frequency

of memory B cells in the total B cell population at visit 1 and visit 3 for matched donors.





